Carbapenem

Antibiotics Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class ; Action Mechanism, and Geography

Retrieved on: 
Thursday, May 7, 2020
Branches of biology, Drugs, Medicine, Hepatotoxins, Antibiotic, Carbapenem, Ofloxacin, Macrolide, Quinolone antibiotic, Penicillin, Aminoglycoside, Sulfonamide

However, expensive process of antibiotic development is likely to pose a negative impact on the market growth, which in turn will restrain the growth of the market during the forecast years.

Key Points: 
  • However, expensive process of antibiotic development is likely to pose a negative impact on the market growth, which in turn will restrain the growth of the market during the forecast years.
  • Such potential increase in prevalence of bacterial infections is expected to continue to drive the growth of antibiotics market during the forecast period.
  • The global antibiotics market is segmented into drug class and action mechanism.Based on drug class, the antibiotics market is segmented into sulfonamides, aminoglycosides, carbapenem, macrolides, fluoroquinolones, penicillin, cephalosporin, and others.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Recce Pharmaceuticals Announces Positive Data on RECCE® 327 Against Neisseria gonorrhoeae in STD Animal Model

Retrieved on: 
Monday, May 4, 2020
Carbapenem antibiotics, Drugs, Organic compounds, Pyrrolidines, Chemistry, Carbapenem, Antibiotic, Recce, Meropenem, Draft:Recce Pharmaceuticals Ltd

In this study Meropenem, a broad spectrum carbapenem antibiotic, was used at its optimum dose as the recognized efficacy model.

Key Points: 
  • In this study Meropenem, a broad spectrum carbapenem antibiotic, was used at its optimum dose as the recognized efficacy model.
  • The FDA has awarded RECCE 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.
  • Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

KBP Biosciences Announces Publication of Potent In Vitro Activity of KBP-7072 Against Acinetobacter baumannii

Retrieved on: 
Tuesday, April 28, 2020
Medicine, Medical specialties, Infectious diseases, Moraxellaceae, Gram-negative bacteria, Healthcare-associated infections, Cyclic peptides, Acinetobacter baumannii, Pathogenic bacteria, Acinetobacter, Carbapenem, Colistin

KBP-7072, demonstrated potent activity against geographically-diverse strains of A. baumannii including carbapenem-resistant, colistin-resistant and tetracycline-resistant isolates.

Key Points: 
  • KBP-7072, demonstrated potent activity against geographically-diverse strains of A. baumannii including carbapenem-resistant, colistin-resistant and tetracycline-resistant isolates.
  • Acinetobacter has become a particularly serious public health problem in China and this includes resistance to antibiotics of last resort.
  • The study evaluated the in vitro activity of KBP-7072 compared to other agents against 531 A. baumannii strains collected in the U.S., Europe, Asia-pacific and Latin America.
  • KBP Biosciences is actively seeking to identify additional promising therapeutic opportunities and further develop its product portfolio.

Shionogi Receives European Commission Marketing Authorisation for FETCROJA® (cefiderocol) for the Treatment of Infections Due to Aerobic Gram-negative Bacteria in Adults With Limited Treatment Options

Retrieved on: 
Tuesday, April 28, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Health, Medicine, Infectious diseases, Healthcare-associated infections, Carbapenem antibiotics, Pneumonia, Carbapenem, Hospital-acquired pneumonia, Hospital-acquired infection, Cefiderocol, Shionogi, Antimicrobial Resistance, cefiderocol access, Shionogi

As a result of COVID-19 some ventilated patients with viral pneumonia may develop secondary carbapenem-resistant Gram-negative bacterial infections.

Key Points: 

Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)

Retrieved on: 
Tuesday, March 31, 2020
Fluoroquinolone antibiotics, Medical specialties, Chemical compounds, Urinary tract infection, Infection, Medicine, RTT, Antibiotics, Carbapenem

Oral and IV sulopenem are being evaluated in pivotal Phase 3 clinical trials for uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra-abdominal infections.

Key Points: 
  • Oral and IV sulopenem are being evaluated in pivotal Phase 3 clinical trials for uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra-abdominal infections.
  • Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with oral and IV formulations.
  • Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
  • These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem, and the timing, progress and results of clinical trials.

Shionogi Receives Positive CHMP Opinion for FETCROJA® (cefiderocol) for the Treatment of Infections Due to Aerobic Gram-Negative Bacteria in Adult Patients With Limited Treatment Options

Retrieved on: 
Monday, March 2, 2020
Medical Supplies, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Carbapenem antibiotics, Carbapenem, Shionogi, Companies, Economy of Japan, Doripenem, FETCROJA® (cefiderocol), Gram-negative infections, Shionogi

If approved, cefiderocol will be an important new treatment option for patients with these particularly difficult to treat Gram-negative infections who have limited options available to them.

Key Points: 
  • If approved, cefiderocol will be an important new treatment option for patients with these particularly difficult to treat Gram-negative infections who have limited options available to them.
  • Infections caused by carbapenem-resistant Gram-negative bacteria are often associated with higher mortality compared to those involving other strains5.
  • The European Commission will review the CHMP opinion and is expected to deliver its final decision later this year.
  • Shionogi B.V. is the European headquarters of Shionogi & Co., Ltd. For more information on Shionogi B.V., please visit www.shionogi.eu .

Shionogi’s FETROJA® (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the U.S.

Retrieved on: 
Monday, February 24, 2020
Health, FDA, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Infectious diseases, RTT, Bacterial diseases, Healthcare-associated infections, Hospital-acquired infection, Intensive care medicine, Hospital-acquired pneumonia, Bacteremia, Antibiotic, Carbapenem, FETROJA® (cefiderocol) for injection, Shionogi

View the full release here: https://www.businesswire.com/news/home/20200224005260/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200224005260/en/
    FETROJA is now available in the U.S. for patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections.
  • FETROJA (cefiderocol) is contraindicated in patients with a known history of severe hypersensitivity to cefiderocol or other beta-lactam antibacterial drugs, or any other component of FETROJA.
  • The safety and efficacy of FETROJA have not been established for the treatment of nosocomial pneumonia, bloodstream infections or sepsis.
  • Reserve FETROJA for use in patients who have limited or no alternative treatment options for the treatment of cUTI.

Newly-developed Tests Achieve 100% Concordance on Superbug Strains from the CDC

Retrieved on: 
Tuesday, January 21, 2020
Medicine, Health, Medical specialties, Drug resistance, Beta-lactam antibiotics, Enterobacteriaceae, Antimicrobial resistance, Evolutionary biology, Carbapenem, Beta-lactamase, Multiple drug resistance, Antibiotic

Dr. Jack Regan, LexaGenes CEO and Founder states, Antibiotic resistance is a big problem.

Key Points: 
  • Dr. Jack Regan, LexaGenes CEO and Founder states, Antibiotic resistance is a big problem.
  • For the second part of the study, 13 different antibiotic resistance tests were used to successfully detect 90 carbapenemase resistant strains and 123 multi-drug resistant strains (carbapenemase + extended-spectrum beta-lactamases).
  • Dr. Regan concludes, We now have tests that will detect bacterial pathogens that carry antimicrobial resistance and are responsible for the most commonly misdiagnosed infections.
  • The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can return results in about 1 hour.

TAXIS Pharmaceuticals Announces CARB-X Award of $3.2 Million, With Potential for an Additional $11.4 Million, to Develop Efflux Pump Inhibitors (EPIs), a New Drug Class to Defeat Multi-Drug Resistant Infections

Retrieved on: 
Tuesday, January 14, 2020
Research, Infectious diseases, Clinical trials, Biotechnology, Health, University, Pharmaceutical, Science, Education, Bacteria, Medicine, Medical specialties, Gram-negative bacteria, Antibiotic-resistant bacteria, Pseudomonadales, Antibiotics, Beta-lactamase, Pseudomonas aeruginosa, Drug resistance, Efflux, Carbapenem

EPIs have the potential to resurrect the therapeutic activity of antibiotics that no longer work against MDR P. aeruginosa bacterial infections.

Key Points: 
  • EPIs have the potential to resurrect the therapeutic activity of antibiotics that no longer work against MDR P. aeruginosa bacterial infections.
  • TAXIS Pharmaceuticals is also eligible for additional funding of up to $11.4 million if certain milestones are met.
  • Specifically, TAXIS Pharmaceuticals EPI drug development program targets MDR P. aeruginosa with an emphasis on extended-spectrum beta-lactamase (ESBL) pathogens, including hospital acquired and ventilator associated infections.
  • Efflux Pump Inhibitors (EPIs) represent a new anti-resistance drug class against Gram-negative MDR pathogens.

Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections

Retrieved on: 
Tuesday, December 10, 2019
Fluoroquinolone antibiotics, Chemical compounds, Medical specialties, Urinary tract infection, Organic compounds, RTT, Infection, Carbapenem antibiotics, Carbapenem, Eravacycline

Serious adverse events unrelated to study treatment were seen in 7.5% of patients on sulopenem and 3.6% of patients on ertapenem.

Key Points: 
  • Serious adverse events unrelated to study treatment were seen in 7.5% of patients on sulopenem and 3.6% of patients on ertapenem.
  • Given these results, oral and IV sulopenem are being evaluated in three pivotal Phase 3 clinical trials of uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra-abdominal infections.
  • Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with oral and IV formulations.
  • Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.